TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 8679353
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal saline 10 ml with lignocaine
Study: 1932606
Drug: Intravenous carbimide
Normalized name: calcium carbimide
DrugBank: Calcium carbimide (DB09116)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous carbimide doses of 0.1, 0.3, 0.6, and 1 mg kg‐1
Study: 1932606
Drug: Oral carbimide
Normalized name: calcium carbimide
DrugBank: Calcium carbimide (DB09116)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral carbimide doses of 1 and 1.5 mg kg‐1
Study: 1932606
Drug: Oral carbimide
Normalized name: calcium carbimide
DrugBank: Calcium carbimide (DB09116)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral carbimide doses of 0.3 and 1 mg kg‐1
Study: 31927343
Drug: CVT‐301 84
Approvals — FDA: no, EMA: no, PMDA: no
Description: CVT‐301 84 mg
Study: 18075285
Drug: Lycopene supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lycopene supplementation (10 mg/day)
Study: 15379366
Drug: Imiquimod cream
Normalized name: Imiquimod Cream
DrugBank: Imiquimod (DB00724)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Imiquimod cream 5%
Study: 12142559
Drug: Adoptive immunotherapy
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adoptive immunotherapy with anti‐CD3‐expanded tumor vaccine draining lymph node lymphocytes (TVDLN) combined with systemic IL‐2 after vaccination with gene-modified autologous tumor cells.
Study: 8610712
Drug: Ipratropium bromide
Normalized name: Ipratropium Bromide
DrugBank: Ipratropium (DB00332)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ipratropium bromide (500 micrograms, nebulized, three times daily)
Study: 8610712
Drug: Albuterol (2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Albuterol (2.5 mg, nebulized, three times daily)
Study: 1707333
Drug: 1 mg
Normalized name: biotin 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg b.i.d. of ketotifen
Study: 1707333
Drug: 2 mg
Normalized name: iodine 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg b.i.d. of ketotifen
Study: 7192125
Drug: fenbufen (1000
Approvals — FDA: no, EMA: no, PMDA: no
Description: fenbufen (1000 mg/d)
Study: 7192125
Drug: acetylsalicylic acid
Normalized name: ACETYLSALICYLIC ACID
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: acetylsalicylic acid (ASA) (3600 mg/d)
Study: 30427749
Drug: 15-valent pneumococcal
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15-valent pneumococcal conjugate vaccine (PCV15)
Study: 20308765
Drug: Zinc and
Normalized name: Zinc and/or zinc compound
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zinc and multivitamin supplement (2mg/kg/day for 6 weeks)
Study: 20308765
Drug: Only multivitamin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Only multivitamin supplement
Study: 15831778
Drug: 12-mg HHER
Approvals — FDA: no, EMA: no, PMDA: no
Description: 12-mg HHER q24h
Study: 15831778
Drug: 3-mg HHIR
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3-mg HHIR q6h
Study: 8919830
Drug: Low flow
Normalized name: high mallow flower extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low flow circuit (fresh gas flow 700 ml/min)
Study: 332465
Drug: Sulfadiazine (SD)
Normalized name: Sulfadiazine
DrugBank: Sulfadiazine (DB00359)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sulfadiazine (SD) 1,000 MG/Trimethoprim (TM) 320 mg
Study: 332465
Drug: Sulfamethoxazole (SM)
Normalized name: Sulfamethoxazole
DrugBank: Sulfamethoxazole (DB01015)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sulfamethoxazole (SM) 1,600 mg/Trimethoprim 320 mg
Study: 29258499
Drug: SMS education
Normalized name: Samarium Sm-153
DrugBank: Samarium Sm-153 (DB12905)
Approvals — FDA: no, EMA: no, PMDA: no
Description: SMS education intervention (daily messages and weekly reminders)
Study: 18713761
Drug: Mirtazapine 30
Normalized name: mirtazapine 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mirtazapine 30 mg
Study: 19567093
Drug: Intravenous iron
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous iron sucrose (200 mg once a week for 4 weeks, then 100 mg once a week for 8 weeks for HD subgroup; 200 mg once a week for 4 weeks, then 200 mg once every other week for 8 weeks for PD subgroup)
Study: 19567093
Drug: Oral medication
Normalized name: Oral Medication Syringe 3mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral medication (ferrous succinate 200 mg tid for 12 weeks)
Study: 19567093
Drug: Intravenous iron
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous iron sucrose (PD subgroup)
Study: 19567093
Drug: EPO +
Normalized name: epoetin alfa
DrugBank: Erythropoietin (DB00016)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: EPO + intravenous iron sucrose
Study: 16734581
Drug: Two two‐piece
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two two‐piece implants placed in a non‐submerged procedure
Study: 16734581
Drug: Two two‐piece
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two two‐piece implants placed in the traditional submerged procedure
Study: 16734581
Drug: Two one‐piece
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two one‐piece dental implants placed in the traditional non‐submerged procedure
Study: 16734581
Drug: Microgap at
Normalized name: rose bengal AT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Microgap at the crestal level in two‐piece implants
Study: 15229957
Drug: Etanercept 25
Normalized name: etanercept 25 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etanercept 25 mg twice weekly by subcutaneous injection
Study: 9150822
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg paroxetine (n = 271)
Study: 9150822
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg maprotiline (n = 273)
Study: 9150822
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg paroxetine (n = 50)
Study: 9150822
Drug: 150 mg
Normalized name: pectin 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 mg maprotiline (n = 40)
Study: 8881802
Drug: Omeprazole 20
Normalized name: omeprazole 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole 20 mg twice daily for four to eight weeks (H pylori negative ulcers)
Study: 8881802
Drug: Omeprazole 20
Normalized name: omeprazole 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole 20 mg twice daily plus amoxycillin 1 g twice daily for the first two weeks (H pylori positive ulcers)
Study: 8881802
Drug: Omeprazole alone
Normalized name: Omeprazole
DrugBank: Omeprazole (DB00338)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Omeprazole alone for four to eight weeks while continuing NSAID therapy (H pylori positive ulcers)
Study: 2805366
Drug: Topical anaesthesia
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical anaesthesia of the nasal mucous membrane
Study: 1099859
Drug: oestradiolvalerate/norgestrel sequential
Approvals — FDA: no, EMA: no, PMDA: no
Description: oestradiolvalerate/norgestrel sequential therapy
Study: 31169952
Drug: Spontaneous ovulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spontaneous ovulation monitored by urinary luteinising hormone (LH)
Study: 31169952
Drug: Induced ovulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Induced ovulation by administration of human chorionic gonadotrophin (hCG)
Study: 26970975
Drug: HSS-Group (closed-loop
Approvals — FDA: no, EMA: no, PMDA: no
Description: HSS-Group (closed-loop system for propofol administration)
Study: 26970975
Drug: Control Group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control Group (manual administration of propofol)
Study: 19339805
Drug: Guidelines group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Guidelines group (ARIA guidelines with ebastine as oral antihistamine)
Study: 12859551
Drug: Free-choice treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Free-choice treatment group
Study: 16764547
Drug: Protein-enriched energy
Normalized name: protein C
DrugBank: Protein C (DB11312)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Protein-enriched energy supplement
Study: 15153734
Drug: Regimen A
Normalized name: CHLOROXYLENOL 5 g in 1000 mL TOPICAL SOAP [REGIMEN ANTIMICROBIAL]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regimen A (3 instillations at 8-hourly intervals in 1 day)
Study: 15153734
Drug: Regimen B
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regimen B (9 instillations at 8-hourly intervals in 3 days)
Study: 11421903
Drug: Ebastine 20
Normalized name: ebastine
DrugBank: Ebastine (DB11742)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ebastine 20 mg once daily for 7 days
Study: 9416721
Drug: Volume loading
Approvals — FDA: no, EMA: no, PMDA: no
Description: Volume loading of 15 ml/kg lactated Ringer's solution
Study: 9416721
Drug: Continuous infusion
Normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous infusion of etilefrine
Study: 8495702
Drug: antibiotic (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: antibiotic (1 day)
Study: 8495702
Drug: antibiotic (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: antibiotic (3 days)
Study: 28724581
Drug: Triple-dose gadolinium
Normalized name: gadolinium
DrugBank: Gadolinium (DB12091)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple-dose gadolinium administration during MRI scans
Study: 16582056
Drug: Cognitive-behavioural therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive-behavioural therapy (CBT), 22 sessions
Study: 12655445
Drug: Hydration solution
Normalized name: Chloral Hydrate
DrugBank: Chloral hydrate (DB01563)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydration solution with 100 mEq/l sodium (regimen B)
Study: 12655445
Drug: Hydration solution
Normalized name: Chloral Hydrate
DrugBank: Chloral hydrate (DB01563)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydration solution with 70 mEq/l sodium (regimen A)
Study: 6726650
Drug: Methadone (0.5,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methadone (0.5, 1.0, or 2.0 times their regular maintenance dose of 40-60 mg)
Study: 23273042
Drug: Deprexis web-based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Deprexis web-based psychological treatment
Study: 17980884
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of ezetimibe and simvastatin
Study: 12351592
Drug: Antimicrobial lozenge
Normalized name: GAUZE,ANTIMICROBIAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antimicrobial lozenge (Bacitracin, Clotrimazole, Gentamicin)
Study: 10399232
Drug: Structum and
Normalized name: Sarocladium strictum
DrugBank: Sarocladium strictum (DB14168)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Structum and ibuprofen (1200 mg/day) for 6 months
Study: 29408866
Drug: Ibuprofen only
Normalized name: Ibuprofen only product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibuprofen only
Study: 7480566
Drug: Labetalol (nonselective
Approvals — FDA: no, EMA: no, PMDA: no
Description: Labetalol (nonselective adrenoceptor antagonist)
Study: 1979499
Drug: Dopaminergic antidepressant
Normalized name: ANTIDEPRESSANTS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dopaminergic antidepressant drugs
Study: 1979499
Drug: Hormone replacement
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hormone replacement therapy (gonadotropins, testosterone)
Study: 1979499
Drug: DA agonist
Normalized name: DAS-181
DrugBank: DAS-181 (DB15313)
Approvals — FDA: no, EMA: no, PMDA: no
Description: DA agonist and/or 5‐HT antagonist drugs
Study: 30835152
Drug: Adjunctive tianeptine
Normalized name: tianeptine
DrugBank: Tianeptine (DB09289)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjunctive tianeptine 37.5 mg/day
Study: 25154734
Drug: Non-ablative fractional
Normalized name: OMIDUBICEL NON-CULTURED FRACTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-ablative fractional laser treatment (three monthly treatments)
Study: 25154734
Drug: Non-ablative fractional
Normalized name: OMIDUBICEL NON-CULTURED FRACTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-ablative fractional laser treatment
Study: 19724023
Drug: Ezetimibe (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ezetimibe (10 mg/day) plus Orlistat (120 mg, 3 times a day with meals)
Study: 19724023
Drug: Ezetimibe (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ezetimibe (10 mg/day) plus Rimonabant (20 mg/day)
Study: 15631659
Drug: Danazol (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Danazol (600 mg/day) or Stanazol (6 mg/day) and ATRA (10 mg/day) for at least 3 months
Study: 11531038
Drug: Aerobic training
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aerobic training programme (13 weeks, twice a week, 1 hour per session)
Study: 9603640
Drug: EPx4 cycles
Approvals — FDA: no, EMA: no, PMDA: no
Description: EPx4 cycles (etoposide 120 mg/m2 i.v. days 1-3 and cisplatin 80 mg/m2 day 1)
Study: 9603640
Drug: EPx6 cycles
Approvals — FDA: no, EMA: no, PMDA: no
Description: EPx6 cycles (etoposide 120 mg/m2 i.v. days 1-3 and cisplatin 80 mg/m2 day 1)
Study: 3420161
Drug: Nifedipine 30
Normalized name: nifedipine 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nifedipine 30 mg 3 times daily
Study: 30296633
Drug: Involuntary treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Involuntary treatment
Study: 30296633
Drug: Dependency for
Normalized name: Vitamin K-dependent protein S
DrugBank: Protein S human (DB13149)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dependency for activities of daily life
Study: 30296633
Drug: Requests for
Approvals — FDA: no, EMA: no, PMDA: no
Description: Requests for involuntary treatment
Study: 30296633
Drug: Application of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Application of involuntary treatment
Study: 20103545
Drug: Pregabalin (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pregabalin (300 mg at 90 minutes preoperatively and 150 mg at 12 and 24 hours postoperatively)
Study: 18211256
Drug: Obstetric gel
Normalized name: chlorhexidine gluconate Topical Cream [Hibitane Obstetric]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Obstetric gel use
Study: 18211256
Drug: No obstetric
Approvals — FDA: no, EMA: no, PMDA: no
Description: No obstetric gel use (Control)
Study: 8402658
Drug: 4‐HPR 200
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4‐HPR 200 mg/daily
Study: 2876722
Drug: Bisoprolol (2.5-40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bisoprolol (2.5-40 mg)
Study: 2876722
Drug: Propranolol (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol (40 and 80 mg)
Study: 2905149
Drug: Atenolol (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atenolol (50 and 100 mg)
Study: 2876722
Drug: Metoprolol (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoprolol (50 and 100 mg)
Study: 26994397
Drug: Cognitive behavior
Normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive behavior therapy for ultra-high risk (CBTuhr)
Study: 22116378
Drug: Yohimbine hydrochloride
Normalized name: Yohimbine Hydrochloride
DrugBank: Yohimbine (DB01392)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Yohimbine hydrochloride (10 mg) combined with virtual reality exposure therapy (VRET)
Study: 22116378
Drug: Placebo combined
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo combined with virtual reality exposure therapy (VRET)
Study: 18640889
Drug: Aromatase inhibitors
Normalized name: Aromatase inhibitors
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aromatase inhibitors (AI) such as anastrozole or letrozole for 5 years
Study: 18640889
Drug: Sequential approach
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential approach of tamoxifen for 2-3 years followed by anastrozole or exemestane for 2-3 years
Study: 10100179
Drug: Combined oral
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined oral contraceptive preparation (20 micrograms of ethinyl estradiol plus 0.15 mg desogestrel)
Study: 8961507
Drug: PFP-2 vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: PFP-2 vaccine
Study: 8684872
Drug: Saline vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline vaccine (control)
Study: 1516602
Drug: Defibrotide 400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Defibrotide 400 mg b.d. for 30 days
Study: 6408669
Drug: Desipramine (150‐350
Approvals — FDA: no, EMA: no, PMDA: no
Description: Desipramine (150‐350 mg/day)
Study: 30001195
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of extra-amniotic Foley's catheter inflated by 30 cm3 of normal saline and 25 micrograms of vaginal misoprostol
Study: 30001195
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of extra-amniotic Foley's catheter and vaginal misoprostol
Study: 2799651
Drug: 1 gm
Normalized name: Ifex 1 GM Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 gm cefazolin in buttock fat, buttock muscle, or by intravenous injection
Study: 1095040
Drug: 0.15 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.15 mg/kg diazepam
Study: 1095040
Drug: 0.30 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.30 mg/kg diazepam
Study: 1095040
Drug: 0.45 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.45 mg/kg diazepam
Study: 19808140
Drug: Temsirolimus (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Temsirolimus (25 mg) administered as a 30-minute intravenous infusion
Study: 19808140
Drug: Temsirolimus (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Temsirolimus (25 mg) administered as a 30-minute intravenous infusion in patients receiving hemodialysis
Study: 1763796
Drug: 50 micrograms
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 micrograms of vaccine
Study: 1455910
Drug: 100 micrograms
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 micrograms of vaccine
Study: 1763796
Drug: 200 micrograms
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 micrograms of vaccine
Study: 1763796
Drug: 400 micrograms
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 micrograms of vaccine
Study: 6130077
Drug: Buspirone (30,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buspirone (30, 60, and 90 mg)
Study: 29231094
Drug: Edoxaban (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Edoxaban (60 mg once daily after 5 days of low-molecular-weight heparin)
Study: 29231094
Drug: Dalteparin (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dalteparin (200 IU/kg once daily for 1 month followed by 150 IU/kg once daily)
Study: 24562789
Drug: Surgical treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surgical treatment (cohort II)
Study: 23197976
Drug: Dipeptidyl peptidase-4
Normalized name: Immature tripeptidyl-peptidase I
DrugBank: Cerliponase alfa (DB13173)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Dipeptidyl peptidase-4 inhibitor (vildagliptin)
Study: 16806875
Drug: daily rhDNase
Approvals — FDA: no, EMA: no, PMDA: no
Description: daily rhDNase
Study: 9871843
Drug: TRH (0.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: TRH (0.4 mg intravenous bolus)
Study: 8714022
Drug: Pulsatile intravenous
Normalized name: PULSATILLA PRATENSIS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pulsatile intravenous administration of oxytocin (OT)
Study: 8714022
Drug: Continuous intravenous
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous intravenous administration of oxytocin (OT)
Study: 27997954
Drug: Intensive Language
Normalized name: Uricalm Intensive
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intensive Language Action Therapy (ILAT)
Study: 24389597
Drug: Atorvastatin (20mg/day)
Normalized name: atorvastatin 20 MG
DrugBank: Atorvastatin (DB01076)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Atorvastatin (20mg/day) for 30 days
Study: 22353460
Drug: Oral‐B Stages
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral‐B Stages 3 toothbrush (MTB)
Study: 17955096
Drug: Lamotrigine with
Normalized name: Lamotrigine
DrugBank: Lamotrigine (DB00555)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lamotrigine with concomitant antipsychotics
Study: 17955096
Drug: Lamotrigine with
Normalized name: Lamotrigine
DrugBank: Lamotrigine (DB00555)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lamotrigine with concomitant valproate, lithium, or antidepressants
Study: 16274805
Drug: Lipid-based nose
Normalized name: guggul lipids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lipid-based nose ointment
Study: 10542930
Drug: Subgroup with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subgroup with fasting lipids > 6.5 mmol/l
Study: 1699888
Drug: 30 ml
Normalized name: Vial M/T 30 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 ml of 0.33% bupivacaine (20 ml 0.5% bupivacaine + 10 ml of N saline)
Study: 1699888
Drug: 20 ml
Normalized name: Exact-Med, 20 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 ml of 0.5% bupivacaine + 10 ml of dextraven-150 (6% solution in 5% dextrose)
Study: 356237
Drug: Proquazone (900
Approvals — FDA: no, EMA: no, PMDA: no
Description: Proquazone (900 mg daily for 3 weeks)
Study: 356237
Drug: Ibuprofen (1200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibuprofen (1200 mg daily for 3 weeks)
Study: 31987456
Drug: Mechanism-based agents
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mechanism-based agents applied in rare cancers
Study: 25760065
Drug: Desensitizing gel
Normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Desensitizing gel applied once per week until remission of pain (T1)
Study: 25760065
Drug: Desensitizing gel
Normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Desensitizing gel applied once per week followed immediately by restoration with resin composite (T2)
Study: 25760065
Drug: Desensitizing gel
Normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Desensitizing gel once per week until remission of pain and then restoration with resin composite (T3)
Study: 22338171
Drug: Low-dose methotrexate
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose methotrexate (MTX) at 10 mg plus low-dose methylprednisolone (MP) at 0.5 mg x kg(‐1) x d(‐1) in Group A
Study: 22338171
Drug: Standard-dose methylprednisolone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard-dose methylprednisolone (MP) at 1-2 mg x kg(‐1) x d(‐1) in Group B
Study: 17705571
Drug: Manidipine 10-20
Normalized name: manidipine 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Manidipine 10-20 mg once daily
Study: 15385735
Drug: Cetirizine (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cetirizine (10 mg/d for 30 days)
Study: 3612823
Drug: Barbach's preorgasmic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Barbach's preorgasmic treatment program